{"id":58837,"date":"2026-03-05T13:41:24","date_gmt":"2026-03-05T05:41:24","guid":{"rendered":"https:\/\/flcube.com\/?p=58837"},"modified":"2026-03-05T13:41:24","modified_gmt":"2026-03-05T05:41:24","slug":"rallybio-to-acquire-candid-therapeutics-in-700m-merger-creates-leading-autoimmune-t-cell-engager-company","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58837","title":{"rendered":"Rallybio to Acquire Candid Therapeutics in $700M+ Merger \u2013 Creates Leading Autoimmune T\u2011Cell Engager Company"},"content":{"rendered":"\n

Rallybio Corporation (NASDAQ:\u202fRLYB<\/a>)<\/strong> and Candid Therapeutics, Inc.<\/strong> announced a definitive merger agreement<\/strong> whereby Rallybio will acquire Candid. The combined entity\u2014operating as Candid Therapeutics, Inc.<\/strong>\u2014will emerge as a global leader in T\u2011cell engager (TCE) therapeutics for autoimmune diseases<\/strong>, with a $700\u202fmillion cash balance<\/strong> funding operations through 2030<\/strong>.<\/p>\n\n\n\n

Transaction Overview<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Acquirer<\/strong><\/td>Rallybio Corporation (NASDAQ:\u202fRLYB)<\/td><\/tr>
Target<\/strong><\/td>Candid Therapeutics, Inc.<\/td><\/tr>
Transaction Structure<\/strong><\/td>Merger<\/td><\/tr>
Combined Company Name<\/strong><\/td>Candid Therapeutics, Inc.<\/td><\/tr>
Ticker Symbol<\/strong><\/td>CDRX<\/strong> (Nasdaq)<\/td><\/tr>
Private Financing<\/strong><\/td>>\u202fUSD\u202f505\u202fmillion<\/strong> (oversubscribed, upsized)<\/td><\/tr>
Combined Cash at Closing<\/strong><\/td>~\u202fUSD\u202f700\u202fmillion<\/strong><\/td><\/tr>
Runway<\/strong><\/td>Funded through 2030<\/strong><\/td><\/tr>
Expected Closing<\/strong><\/td>Mid\u20112026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Candid TCE Pipeline<\/h2>\n\n\n\n
Asset<\/th>Target<\/th>Indication Focus<\/th><\/tr><\/thead>
Cizutamig<\/strong><\/td>BCMA TCE<\/td>Myasthenia gravis, ILD secondary to rheumatological diseases<\/td><\/tr>
CND261<\/strong><\/td>CD20 TCE<\/td>Autoimmune diseases (B\u2011cell mediated)<\/td><\/tr>
CND319<\/strong><\/td>Dual CD19\/CD20 TCE<\/td>Broad B\u2011cell and plasma cell depletion<\/td><\/tr>
Portfolio<\/strong><\/td>10+ indications ongoing<\/td>Spanning B\u2011cell and plasma cell targets<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Milestones<\/h2>\n\n\n\n
Program<\/th>Milestone<\/th>Timeline<\/th><\/tr><\/thead>
Cizutamig<\/strong><\/td>Phase 2 initiation (myasthenia gravis)<\/td>Near\u2011term<\/td><\/tr>
Cizutamig<\/strong><\/td>Phase 2 clinical readouts<\/td>2026\u20112027<\/td><\/tr>
CND261\/CND319<\/strong><\/td>Multiple autoimmune indications<\/td>Through 2030<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Leadership<\/h2>\n\n\n\n
Role<\/th>Appointment<\/th><\/tr><\/thead>
Chairman, President, CEO<\/strong><\/td>Dr. Ken Song (current Candid CEO)<\/td><\/tr>
Management Expertise<\/strong><\/td>Autoimmune drug development, TCE biology, global clinical operations<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Implications<\/h2>\n\n\n\n